FrancophonIA/ELRC3.0 huggingface dataset:
English: This medicinal product must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line.
Estonian: Seda ravimpreparaati ei tohi segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega ja peab manustama üksiku intravenoosse lahusena eraldi infusioonivooliku kaudu.
English: Placebo zoledronic acid 4 mg
Estonian: Platseebo Zoledroonhape 4 mg
English: Multi-packs containing 10 (10 packs of 1) vials.
Estonian: Hulgipakend sisaldab 10 (10 üksikpakendit) viaali.
English: Table 3 Efficacy results (prostate cancer patients receiving hormonal therapy)
Estonian: Tabel 3 Kliinilise uuringu tulemuste kokkuvõte (hormoonravi saavad prostatavähi patsiendid)
English: Efficacy results are provided in Table 3.
Estonian: Uuringu tulemuste kokkuvõte on toodud tabelis 3.
English: Zometa concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line.
Estonian: Zometa kontsentraati ei tohi segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonivooliku kaudu.
English: Clinical trial results in the prevention of skeletal related events in patients with advanced malignancies involving bone
Estonian: Kliiniliste uuringute tulemused luustikuga seotud tüsistuste vältimisel luukude haarava kaugelearenenud pahaloomulise kasvajaga patsientidel
English: Zometa 4 mg/100 ml solution for infusion zoledronic acid
Estonian: Zometa 4 mg/100 ml infusioonilahus acidum zoledronicum
English: Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of 4 mg zoledronic acid on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period.
Estonian: 4 mg zoledroonhappe toime hindamiseks luustikuga seotud tüsistuste (LST) suhte määrale, mille arvutamiseks LST (välja arvatud hüperkaltseemia ja täpsustatud varasem luumurd) koguarvu jagatuna riskiperioodiga, uuriti topeltpimedas, randomiseeritud platseebokontrolliga uuringus 228 patsienti, kelle rinnavähi metastaaside esinemine luukoes oli dokumenteeritud.
English: The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:
Estonian: Järgnevalt on tabelis 1 loetletud kõrvaltoimed, mis registreeriti 4 mg zoledroonhappe peamiselt pikemaajalise ravi kliinilistes uuringutes ja turuletulekujärgsetes teadetes.
English: Skin reactions (redness and swelling) at the infusion site, rash, itching.
Estonian: Nahareaktsioonid (punetus ja turse) infusioonikohas, lööve, sügelus.
English: As a consequence of low calcium values: seizures, numbness and tetany (secondary to hypocalcaemia).
Estonian: Madal kaltsiumisisaldus veres võib põhjustada: krampe, tuimust ja tetaaniat (sekundaarsena hüpokaltseemiast).
English: FOLDING BOX FOR 1 VIAL AND 1 AMPOULE AS INTERMEDIATE PACK (WITHOUT BLUE BOX)
Estonian: 1 VIAALI JA 1 AMPULLI SISALDAV KOKKUVOLDITAV KARP SISEPAKENDIKS (ILMA "BLUE BOX"'ITA)
English: The following adverse reactions, listed in Table 2, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:
Estonian: Järgnevalt on tabelis 2 loetletud kõrvaltoimed, mis registreeriti 4 mg zoledroonhappe peamiselt pikemaajalise ravi kliinilistes uuringutes ja turuletulekujärgsetes teadetes.
English: Irregular heart beat (cardiac arrhythmia), seizures, spasm and twitching (tetany) have been reported as secondary to severe hypocalcaemia.
Estonian: Teatatud on ka südame rütmihäiretest (südame arütmia), krampidest, spasmidest ja kangestuskrampidest (tetaania), mis tekkisid hüpokaltseemia raskete juhtude tagajärjel.
English: Table 5 Efficacy results (breast cancer and multiple myeloma patients)
Estonian: Tabel 5 Kliinilise uuringu tulemuste kokkuvõte (hulgimüeloomi ja rinnavähiga patsiendid)
English: Solvent for Zometa Water for injections 5 ml
Estonian: Zometa lahusti Süstevesi 5 ml
English: Withdraw an appropriate volume of the reconstituted solution (4 mg/5 ml) as needed: - 4.4 ml for 3.5 mg dose
Estonian: Juhend vähendatud annusega Zometa lahuse valmistamiseks: Võtke lahjendatud lahusest (4 mg/5 ml) vajalik kogus: 4,4 ml lahust 3,5 mg annuse valmistamiseks
English: What Zometa looks like and contents of the pack Zometa is supplied as a liquid concentrate in a vial.
Estonian: Zometa't turustatakse vedela kontsentraadina viaalides.
English: Zometa 4 mg/5 ml concentrate for solution for infusion
Estonian: Zometa 4 mg/5 ml infusioonilahuse kontsentraat
English: Zometa treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment.
Estonian: Tuumorist indutseeritud hüperkaltseemiaga patsientidel ja neil, kelle neerufunktsioon on kahjustunud, tuleb hinnata ravi võimaliku kasu ja riski vahekorda.
English: Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid (see section 4.4).
Estonian: Pärast 4 mg zoledroonhappe algannuse või ühekordse annuse manustamist on patsientidel registreeritud neerufunktsiooni halvenemist, neerukahjustuse ja dialüüsivajaduse teket (vt lõik 4.4).
English: General disorders and administration site conditions Common:
Estonian: Üldised häired ja manustamiskoha reaktsioonid sage:
English: After dilution: From a microbiological point of view, the diluted solution for infusion should be used immediately.
Estonian: Pärast lahjendamist: Mikrobioloogilise puhtuse tagamiseks tuleb lahjendatud infusioonilahus kasutada koheselt peale avamist.
English: After first opening: From a microbiological point of view, the solution for infusion should be used immediately.
Estonian: Kasutamine peale avamist: Mikrobioloogilise puhtuse tagamiseks tuleb infusioonilahus kasutada koheselt peale avamist.
English: Increases in serum creatinine also occur in some patients with chronic administration of Zometa at recommended doses for prevention of skeletal related events, although less frequently.
Estonian: Kreatiniini sisaldus seerumis võib tõusta patsiendil, kes on luustikuga seotud tüsistuste vältimiseks saanud pikemat aega soovitatud annuses Zometa't.
English: In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30-60 ml/min, reduced Zometa doses are recommended (see also section 4.4).
Estonian: Kerge kuni keskmise neerupuudulikkusega luumetastaasidega patsientidele kreatiniinikliirensiga 30…60 ml/min on ravi alustamiseks soovitatavad järgmised madalamad Zometa annused (vt lõik 4.4).
English: Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone.
Estonian: Võtke ühendust oma arstiga, kui tunnete valu, nõrkust või ebamugavustunnet reies, puusas või kubemes.
English: FOLDING BOX - OUTER CONTAINER OF MULTIPACK (WITH BLUE BOX)
Estonian: KARP - HULGIPAKENDI VÄLISPAKEND ("BLUE BOX'ITA")
English: One vial with 5 ml concentrate contains 4 mg zoledronic acid, corresponding to 4.264 mg zoledronic acid monohydrate.
Estonian: Üks viaal 5 ml kontsentraadiga sisaldab 4 mg zoledroonhapet, mis vastab 4,264 mg zoledroonhappe monohüdraadile.
English: Dyspnoea, cough, bronchoconstriction
Estonian: Düspnoe, köha, bronhokonstriktsioon harv interstitsiaalne kopsuhaigus
English: Do not mix Zometa reconstituted solution with calcium-containing or other divalent cation-containing solutions such as lactated Ringer's solution.
Estonian: Ärge lahjendage Zometa lahust kaltsiumi või muid bivalentseid katioone sisaldava lahusega, nt Ringeri laktaatlahusega.
English: Common (may affect up to 1 in 10 people):
Estonian: Sage (võivad esineda kuni 1 inimesel 10-st):
English: From a microbiological point of view, the solution for infusion should be used immediately, after first opening.
Estonian: Mikrobioloogilise puhtuse tagamiseks tuleb infusioonilahus kasutada koheselt peale avamist.
English: Hypophosphataemia
Estonian: Infusioonilahus
English: Zometa reconstituted solution must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line.
Estonian: Zometa lahust ei tohi segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonivooliku kaudu.
English: Chest pain.
Estonian: Valu rinnus.
English: Very rare:
Estonian: uveiit väga harv:
English: In patients who show evidence of renal deterioration during treatment, Zometa should be withheld.
Estonian: Kui Zometa-ravi jooksul neerupuudulikkus süveneb, tuleb ravi katkestada.
English: Table 4 Efficacy results (breast cancer and multiple myeloma patients)
Estonian: Tabel 4 Kliinilise uuringu tulemuste kokkuvõte (hulgimüeloomi ja rinnavähiga patsiendid)
English: Gastrointestinal reactions such as nausea and vomiting as well as loss of appetite.
Estonian: Mao-seedetrakti häired, nt iiveldus, oksendamine ja isutus.
English: Multipack comprising 5 packs, each containing 1 bottle.
Estonian: Hulgipakend koosneb 5 karbist, milles igaühes on 1 pudel.
English: The adverse reactions ranked under headings of frequency, are presented in Table 6.
Estonian: tabelis 6 on kõrvaltoimed loetletud esinemissageduse järgi.
English: Rare:
Estonian: aeg-ajalt:
English: Component of a multipack comprising 4 packs, each containing 1 bottle.
Estonian: Osa hulgipakendist, mis koosneb 4 karbist, milles igaühes on 1 pudel.
English: From a microbiological point of view, the diluted solution for infusion should be used immediately.
Estonian: - Mikrobioloogilise puhtuse tagamiseks tuleb lahjendatud infusioonilahus koheselt ära kasutada.
English: Multipack comprising 4 packs, each containing 1 bottle.
Estonian: Hulgipakend koosneb 4 karbist, milles igaühes on 1 pudel.
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C - 8°C.
Estonian: Kui infusioonilahus ei ole koheselt kasutatud, siis kasutusaegade ja -tingimuste täitmise eest vastutab kasutaja ning see ei tohiks ületada 24 tundi 2°C - 8°C.
English: It also contains mannitol, sodium citrate and water for injections.
Estonian: Viaal sisaldab mannitooli, naatriumtsitraati ja süstevett.
English: Component of a multipack comprising 5 packs, each containing 1 bottle.
Estonian: Osa hulgipakendist, mis koosneb 5 karbist, milles igaühes on 1 pudel.
English: Prevention of skeletal related events in patients with advanced malignancies involving bone Adults and older people
Estonian: Luustikuga seotud tüsistuste vältimine luukude haarava kaugelearenenud pahaloomulise kasvajaga patsientidel
English: Zometa 4 mg powder and solvent for solution for infusion, reconstituted and further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes.
Estonian: Lahustatud ja 100 milliliitrini lahjendatud (vt lõik 6.6) Zometa 4 mg infusioonilahuse pulber ja lahusti tuleb manustada ühe intravenoosse infusioonina vähemalt 15 minuti kestel.
English: Stable for 24 hours at 2C - 8C after further dilution in 100 ml physiological saline or 5% w/v glucose solution.
Estonian: Pärast lahjendamist 100 ml füsioloogilises lahuses või 5% glükoosilahuses on temperatuuril 2C...8C stabiilne 24 tundi.
English: The withdrawn amount of reconstituted solution must be diluted in 100 ml of sterile 0.9% w/v sodium chloride solution or 5% w/v glucose solution.
Estonian: Vajaliku annuse valmistamiseks võetud lahus tuleb lahjendada 100 ml steriilse 0,9% naatriumkloriidi- või 5% glükoosilahusega.
English: To avoid potential incompatibilities, Zometa concentrate is to be diluted with 0.9% w/v sodium chloride solution or 5% w/v glucose solution.
Estonian: Sobimatuse vältimiseks tuleb Zometa kontsentraati lahjendada 0,9% naatriumkloriidi- või 5% glükoosilahusega.
English: Confusion
Estonian: Annustamine
English: One vial with 5 ml concentrate for solution for infusion.
Estonian: Ühes viaalis on 5 ml infusioonilahuse valmistamise kontsentraati.
English: MARKETING AUTHORISATION NUMBERS
Estonian: Müügiloa hoidja logo
English: The withdrawn amount of concentrate must be further diluted in 100 ml of sterile 0.9% w/v sodium chloride solution or 5% w/v glucose solution.
Estonian: Vajaliku annuse valmistamiseks võetud kontsentraat tuleb lahjendada 100 ml steriilse 0,9% naatriumkloriidi- või 5% glükoosilahusega.
English: Bone pain, myalgia, arthralgia, generalised pain
Estonian: luuvalu, müalgia, liigesvalu, generaliseerunud valu.
English: Ask your doctor for advice before taking any medicine while you are pregnant or breast-feeding.
Estonian: Kui olete rase või toidate last rinnaga, pidage enne ravimi kasutamist nõu oma arstiga.
English: if you have or have had pain, swelling or numbness of the jaw, a feeling of heaviness in the jaw or loosening of a tooth.
Estonian: teil on olnud või on lõualuu valu, turse või tuimus, raskustunne lõualuus või hammaste logisemine.
English: Zometa 4 mg powder for solution for infusion zoledronic acid
Estonian: Zometa 4 mg infusioonilahuse pulber ja lahusti acidum zoledronicum
English: Pregnancy
Estonian: süstevesi
English: Zometa 4 mg/5 ml concentrate for solution for infusion zoledronic acid
Estonian: Zometa 4 mg/5 ml infusioonilahuse kontsentraat acidum zoledronicum
English: From a microbiological point of view, the reconstituted and diluted solution for infusion should be used immediately.
Estonian: Mikrobioloogilise puhtuse tagamiseks tuleb infusioonilahus kasutada koheselt peale lahustamist ja lahjendamist.
English: Table 3 Efficacy results (solid tumours other than breast or prostate cancer)
Estonian: Tabel 3 Kliinilise uuringu tulemuste kokkuvõte (soliidtuumoritega patsiendid, v.a. prostataja rinnavähk)
English: Uncommon:
Estonian: Aneemia aeg-ajalt:
English: Table 4 Efficacy results (solid tumours other than breast or prostate cancer)
Estonian: Tabel 4 Kliinilise uuringu tulemuste kokkuvõte (soliidtuumoritega patsiendid, v.a. prostataja rinnavähk)
English: The hydration status of patients must be assessed prior to and following administration of Zometa to assure that they are adequately hydrated.
Estonian: Enne ja pärast ravimi manustamist tuleb kontrollida, kas patsient on piisavalt hüdreeritud.
English: FOLDING BOX FOR 1 VIAL AND 1 AMPOULE AS UNIT PACK (INCLUDING BLUE BOX) FOLDING BOX FOR 4 VIALS AND 4 AMPOULES AS UNIT PACK (INCLUDING BLUE BOX
Estonian: 4 VIAALI JA 4 AMPULLI SISALDAV KOKKUVOLDITAV KARP (KAASA ARVATUD "BLUE BOX")
English: The amount of reconstituted solution as required is then further diluted with 100 ml of calcium-free infusion solution (0.9% w/v sodium chloride solution or 5% w/v glucose solution).
Estonian: Kui pulber on täielikult lahustunud, tuleb vajalik kogus saadud lahust lahjendada 100 ml kaltsiumit mittesisaldava infusioonilahusega (0,9% naatriumkloriidi- või 5% glükoosilahusega).
English: Patients should have their serum creatinine levels assessed prior to each dose of Zometa.
Estonian: Enne iga Zometa annuse manustamist tuleb määrata patsiendil seerumi kreatiniinisisaldus.
English: To avoid potential incompatibilities, the infusion solution used for dilution must be either 0.9% w/v sodium chloride or 5% w/v glucose solution.
Estonian: Sobimatuse vältimiseks tuleb Zometa lahus lahjendada 0,9% naatriumkloriidi- või 5% glükoosilahusega.
English: What Zometa looks like and contents of the pack Zometa is supplied as a powder in a vial.
Estonian: Kuidas Zometa välja näeb ja pakendi sisu
English: Uncommon (may affect up to 1 in 100 people):
Estonian: Aeg-ajalt (võivad esineda kuni 1 inimesel 100-st):
English: Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid.
Estonian: Pärast 4 mg zoledroonhappe esimese või ühekordse annuse manustamist on patsientidel esinenud neerufunktsiooni kahjustust, mis progresseerus kuni neerupuudulikkuse ja dialüüsivajaduseni.
English: Skin and subcutaneous tissue disorders Uncommon:
Estonian: lihasspasmid, lõualuu osteonekroos väga harv:
English: Keep Zometa out of the reach and sight of children.
Estonian: Zometa't tuleb hoida laste eest varjatud ja kättesaamatus kohas.
English: Uveitis
Estonian: Imetamine
English: FOLDING BOX - INTERMEDIATE CONTAINER OF MULTIPACK (WITHOUT BLUE BOX)
Estonian: KARP - HULGIPAKENDI VAHETU SISEPAKEND ("BLUE BOX'ITA")
English: The solvent ampoule contains water for injections.
Estonian: Lahusti ampullis on süstevesi.
English: One vial contains 4 mg zoledronic acid, corresponding to 4.264 mg zoledronic acid monohydrate.
Estonian: Üks viaal sisaldab 4 mg zoledroonhapet, mis vastab 4,264 mg zoledroonhappe (acidum zoledronicum) monohüdraadile.
English: 1 bottle contains 4 mg zoledronic acid, corresponding to 4.264 mg zoledronic acid monohydrate.
Estonian: 1 pudel sisaldab 4 mg zoledroonhapet, mis vastab 4,264 mg zoledroonhappe monohüdraadile.
English: One bottle contains 4 mg zoledronic acid, corresponding to 4.264 mg zoledronic acid monohydrate.
Estonian: Üks pudel sisaldab 4 mg zoledroonhapet, mis vastab 4.264 mg zoledroonhappe monohüdraadile.
English: Placeb o zoledronic acid 4 mg
Estonian: Zoledroonhape 4 mg
English: Tell your doctor and dentist immediately if you experience such symptoms while being treated with Zometa or after stopping treatment.
Estonian: Kui teil esinevad need sümptomid Zometa-ravi ajal või pärast ravi lõppu, rääkige sellest kohe oma arstile ja hambaarstile.
English: Component of a multipack comprising ten packs, each containing one vial and one ampoule
Estonian: Kümmet karpi sisaldava hulgipakendi osa; igas karbis on üks viaal ja üks 5 ml ampull lahustit
English: The measure of effectiveness was levels of antibodies before and after vaccination.
Estonian: Efektiivsuse põhinäitaja oli antikehade sisaldus enne ja pärast vaktsineerimist.
English: Responses in puppies were lower than adult dogs in some cases, because of antibodies inherited from their mothers.
Estonian: Mõnel juhul oli kutsikate immuunvastus väiksem kui täiskasvanud koertel emalt saadud antikehade tõttu.
English: The dogs were either vaccinated twice with a three or four week interval or they received a single annual booster vaccination.
Estonian: Koeri vaktsineeriti kaks korda kolme- või neljanädalase intervalliga või neile manustati üks kord aastas üks kordusvaktsiini annus.
English: In case of accidental self-injection, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
Estonian: Juhusliku enesesüstimise korral tuleb pöörduda kohe arsti poole ja näidata ravimi pakendi infolehte või etiketti.
English: In situations where puppies are expected to inherit very high antibody levels from the bitch the vaccination protocol should be planned accordingly.
Estonian: Olukordades, kus võib eeldada, et kutsikas on saanud emalt väga palju antikehi, tuleb vaktsineerimiskava vastavalt kohandada.
English: The vaccine is given to puppies from six weeks of age as an injection, under the skin, and repeated three to four weeks later.
Estonian: Vaktsiini süstitakse kutsikatele naha alla alates 6 nädala vanusest ja veel üks kord 3…4 nädalat hiljem.
English: Versican Plus Pi/L4 is a veterinary vaccine that contains live attenuated (weakened) canine parainfluenza virus type 2 as well as inactivated (killed) strains of Leptospira bacteria (Icterohaemorrhagiae, Canicola, Bratislava and Grippotyphosa).
Estonian: Versican Plus Pi/L4 on veterinaarvaktsiin, mis sisaldab koerte paragripi 2. tüüpi viiruse nõrgestatud elusvorme ning Leptospira bakterite inaktiveeritud (hävitatud) tüvesid (Icterohaemorrhagiae, Canicola, Bratislava ja Grippotyphosa).
English: In the future, if the animals are exposed to these viruses or bacteria again the immune system will be able to respond more quickly.
Estonian: Kui loomad puutuvad hiljem nende viiruste ja bakteritega uuesti kokku, tekivad antikehad kiiremini.
English: The effectiveness of Versican Plus Pi/L4 was investigated in a field study involving 129 dogs.
Estonian: Vaktsiini Versican Plus Pi/L4 efektiivsust uuriti väliuuringus, kus osales 129 koera.
English: This summary was last updated in June 2014.
Estonian: Kokkuvõtte viimane uuendus: 06-2014.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Versican Plus Pi/L4 on 31 July 2014.
Estonian: Euroopa Komisjon andis vaktsiini Versican Plus Pi/L4 müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 31. juulil 2014.
English: This will help protect them against kennel cough and leptospirosis.
Estonian: See aitab kaitsta loomi trahheobronhiidi ja leptospiroosi eest.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Versican Plus Pi/L4 exceed the risks for the approved indications and recommended that Versican Plus Pi/L4 be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et heakskiidetud näidustustel on vaktsiini Versican Plus Pi/L4 kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini Versican Plus Pi/L4 müügiloa.
English: The field study showed that after vaccination with Versican Plus Pi/L4 the percentage of dogs with protective levels of antibodies for parainfluenza virus ranged from 73 to 97% and for leptospira 59 to 96%.
Estonian: Väliuuring näitas, et pärast vaktsineerimist vaktsiiniga Versican Plus Pi/L4 oli uuringus koeri, kelle organismis oli piisavalt paragripiviiruse vastaseid antikehi, 73-97%, ja leptospiroosi vastased antikehi, 59-96%.
English: • canine parainfluenza virus, which causes kennel cough;
Estonian: • koerte paragripiviirus, mis põhjustab trahheobronhiiti;
English: The benefit-risk balance may be found in the scientific discussion module of this EPAR.
Estonian: Ravimi kasulikkuse ja riski suhe on käesoleva Euroopa avaliku hindamisaruande teadusliku arutelu jaotises.
English: For revaccination a single dose of Versican Plus Pi/L4 is required annually.
Estonian: Kordusvaktsineerimiseks tuleb manustada üks annus vaktsiini Versican Plus Pi/L4 üks kord aastas.
English: Canine parainfluenza virus (live attenuated) and canine leptospirosis (inactivated) vaccine
Estonian: Koerte paragripiviiruse vaktsiin (nõrgestatud elusvaktsiin) ja koerte leptospiroosi vaktsiin (inaktiveeritud)
English: When Versican Plus Pi/L4 is given to dogs the animals' immune system recognises the viruses and bacteria as ‘foreign' and makes antibodies against them.
Estonian: Kui koertele manustatakse vaktsiini Versican Plus Pi/L4, peab immuunsüsteem viiruseid ja baktereid võõraks ning tekitab nende vastu antikehi.
English: Versican Plus Pi/L4 contains an adjuvant (aluminium hydroxide) to enhance the immune response.
Estonian: Versican Plus Pi/L4 sisaldab immuunvastuse tugevdamiseks adjuvanti (alumiiniumhüdroksiid).
English: Versican Plus Pi/L4 is used to protect dogs against:
Estonian: Vaktsiini Versican Plus Pi/L4 kasutatakse koerte kaitsmiseks järgmiste haiguste eest:
English: Versican Plus Pi/L4 is a vaccine.
Estonian: Versican Plus Pi/L4 on vaktsiin.
English: The most common side effect (seen in more than 1 in 100 dogs) with Versican Plus Pi/L4 is a short lived swelling of up to 5 cm which may occur at the injection site after vaccination.
Estonian: Vaktsiini Versican Plus Pi/L4 kõige sagedam kõrvalnäht (esinenud enam kui 1 koeral 100st) on kuni 5 cm suurune mööduv turse süstekohal.